DEMETRIS GREEN: Open Payments
NPI 1699973420 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,695 in 76 payments from 21 companies in 2025. Trend: 2023 $3,328 · 2024 $2,570 · 2025 $3,695
Food & beverage: $3,695
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $492 |
| Novo Nordisk Inc | 14 | $474 |
| Bayer Healthcare Pharmaceuticals Inc. | 12 | $437 |
| Amgen Inc. | 9 | $334 |
| Inspire Medical Systems, Inc. | 4 | $303 |
| Gilead Sciences, Inc. | 2 | $242 |
| Indivior Inc. | 3 | $164 |
| ABBVIE INC. | 2 | $151 |
| Kowa Pharmaceuticals America, Inc. | 5 | $151 |
| Lilly USA, LLC | 2 | $137 |
Products named: Kerendia, INSPIRE, BREZTRI, Ozempic, REPATHA, SUBLOCADE, QULIPTA, ZORYVE.
Industry payments across TX — which companies pay providers there.
